The biology of Kit in disease and the application of pharmacogenetics.
about
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyReview article: the biology, diagnosis and management of gastrointestinal stromal tumoursThe c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyPrognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.Eosinophilia in mast cell diseaseMast cell activation syndrome as a significant comorbidity in sickle cell disease.Immunohistochemical evaluation of AKT protein activation in canine mast cell tumoursClonality and molecular pathogenesis of mastocytosis.Mast cells and mastocytosis.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.The mast cell and allergic diseases: role in pathogenesis and implications for therapy.Stem cell-based therapy in gastroenterology and hepatology.Utility of hydroxyurea in mast cell activation syndrome.Complex chemoattractive and chemorepellent Kit signals revealed by direct imaging of murine mast cells in microfluidic gradient chambers.Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.Indolent systemic mastocytosis limited to the bone: a case report and review of the literature.Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis.Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease.Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options.Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation.Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.Urticaria pigmentosa-like disease in a dog.Therapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model study.Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis.Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125.The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice.Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa.
P2860
Q24685914-83EC11DB-5918-4585-BC84-8D3B5A224ED4Q26825310-A1220C23-AB32-4F44-85CB-FAD7DBE05E4DQ27824853-C9B28611-3B07-4D55-9007-A46E5B94CE8AQ33423072-610E7896-660C-491D-8A85-7224BA1FCAAAQ33485242-7D2BCE44-344C-4688-B7C0-C5C1037C7BA4Q33851724-0B29C7E7-B092-4648-8830-A243BE6764A3Q34564293-35D14BB7-DDC4-4456-A1C4-DEAEE23BC5F8Q35926007-C5FF0436-179F-4104-A735-339E0999DAB1Q36182758-7B49EE5E-8C32-47EC-BAE7-90378A9C33F6Q36835143-63A1D04A-8BF1-42FF-9EC6-D10404D20693Q36842503-69EF22B2-434C-4E85-B8CD-BAB9C0FB250CQ37010493-6D33975B-7646-44A1-B1D3-5EE8CEDA0623Q37157674-45F09627-8383-4B20-AE9E-EBBC4C5F5E34Q37365376-18CC2AC2-BBD8-4D08-980D-F0ADEA36861DQ37680779-62F20023-447A-4206-B6A5-6B2B78368E51Q37892475-E1E43E09-B99A-40E4-9066-50FBF4AC719BQ38125573-01B5D7D6-1DD0-4127-B1D6-31104F20B3D9Q38504083-C64A247D-DA8F-4763-B0B0-2C5D57873D26Q38582624-ED951F8A-F8FA-4CD0-B661-B6B2714BB913Q38788064-A1CF7319-85DC-46B6-ADF3-657EE6C5E797Q40091176-123E5271-671C-4E4F-AC59-DD2462846D10Q40199177-7F9A5EF8-A4DA-4D28-8860-28F5841285F9Q41604021-2E0E3E83-2511-4841-BE53-4178462DD8FDQ43145475-E864DB9A-3F21-4736-8B9E-3EC58A790CD4Q47572183-715E1360-634D-44E7-AFDE-AD11931D8552Q51121916-43A62171-C2CA-4F95-BB35-DCBBF36DE7FEQ53459692-1F20D298-8318-4C25-AFF9-9E22B6389F87Q53604077-01B8CD6B-1DD1-4639-98BF-9972E5FFCE3FQ54234141-929391E5-88D2-43FC-82F3-63A18D4D3B60Q54558599-A3B1C935-A0FB-4312-BAA8-8FF479D88813Q54566864-74B851D2-131F-42EA-B298-0704B02E3C8B
P2860
The biology of Kit in disease and the application of pharmacogenetics.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The biology of Kit in disease and the application of pharmacogenetics.
@ast
The biology of Kit in disease and the application of pharmacogenetics.
@en
type
label
The biology of Kit in disease and the application of pharmacogenetics.
@ast
The biology of Kit in disease and the application of pharmacogenetics.
@en
prefLabel
The biology of Kit in disease and the application of pharmacogenetics.
@ast
The biology of Kit in disease and the application of pharmacogenetics.
@en
P1476
The biology of Kit in disease and the application of pharmacogenetics.
@en
P2093
Dean D Metcalfe
P304
13-9; quiz 20
P356
10.1016/J.JACI.2004.04.046
P407
P577
2004-07-01T00:00:00Z